Literature DB >> 2392500

Chronic low-dose haloperidol effects on self-stimulation rate-intensity functions.

M R Lynch1, R J Carey.   

Abstract

Animals responding for biphasic square wave stimulation to the VTA were treated for 26 days with a low dose (0.07 mg/kg) of the neuroleptic haloperidol and tested at 1 h post-injection. Initially the drug induced a pronounced lateral displacement of the baseline rate-intensity function, concomitant with a depression in slope. Over the course of chronic treatment, partial tolerance was observed to the drug-induced increases in threshold concomitant with the onset of a significant suppression in peak response rate. Biochemical tolerance to stimulated dopamine metabolism (as per cent non-drug control) was significant only for mesolimbic (versus neostriatal) regions, in animals receiving haloperidol according to pre- and post-test administration schedules. The observation of sensitization to peak rate reductions parallels previous reports for spontaneous locomotor activity measures and is compatible with depolarization inactivation mechanisms proposed to account for delayed-onset clinical effects. Further, selective biochemical tolerance in mesolimbic regions supports suggestions that mesolimbic dopamine is important as a substrate for subtle low dose neuroleptic effects which may be relevant for studying pharmacotherapeutic treatment issues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392500     DOI: 10.1007/bf02245756

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Effects of pimozide on positive and negative incentive contrast with rewarding brain stimulation.

Authors:  A G Phillips; F G LePiane
Journal:  Pharmacol Biochem Behav       Date:  1986-06       Impact factor: 3.533

Review 2.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

3.  Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences.

Authors:  L A Chiodo; B S Bunney
Journal:  J Neurosci       Date:  1987-03       Impact factor: 6.167

4.  Neuroleptics and brain self-stimulation behavior.

Authors:  A Wauquier
Journal:  Int Rev Neurobiol       Date:  1979       Impact factor: 3.230

5.  Simultaneous multiple electrode liquid chromatographic-electrochemical assay for catecholamines, indole-amines and metabolites in brain tissue.

Authors:  G S Mayer; R E Shoup
Journal:  J Chromatogr       Date:  1983-01-21

6.  Does pimozide block the reinforcing effect of brain stimulation?

Authors:  C R Gallistel; M Boytim; Y Gomita; L Klebanoff
Journal:  Pharmacol Biochem Behav       Date:  1982-10       Impact factor: 3.533

7.  The curve-shift paradigm in self-stimulation.

Authors:  E Miliaressis; P P Rompre; P Laviolette; L Philippe; D Coulombe
Journal:  Physiol Behav       Date:  1986

8.  Haloperidol and light reinforcement in the rat.

Authors:  G Lowe
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

9.  Differential effects of haloperidol and clozapine on attention.

Authors:  M Cheal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol.

Authors:  G D Vogelsang; M F Piercey
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

View more
  2 in total

Review 1.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

2.  Microcatalepsy and disruption of forelimb usage during operant behavior: differences between dopamine D1 (SCH-23390) and D2 (raclopride) antagonists.

Authors:  S C Fowler; J R Liou
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.